Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Enzon Pharmaceuticals Inc. (ENZND : OTC)

• Company Description    Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $6.19 Daily Weekly Monthly 20 Day Moving Average: 1,322 shares Shares Outstanding: 0.74 (millions) Market Capitalization: $4.60 (millions) Beta: -0.04 52 Week High: $12.99 52 Week Low: $3.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.19% 5.66% 12 Week 52.88% 61.79% Year To Date 63.37% 69.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 Commerce Drive Suite 135 - Cranford,NJ 07016 USA ph: 732-980-4500 fax: 732-980-4585 investor@enzon.com http://www.enzon.com

• General Corporate Information    Officers Richard L. Feinstein - Chief Executive Officer; Chief Financial Officer a Randolph C. Read - Chairman Jordan Bleznick - Director Jaffray A. Firestone - Director Stephen T. Wills - Director Peer Information Enzon Pharmaceuticals Inc. (CORR.) Enzon Pharmaceuticals Inc. (RSPI) Enzon Pharmaceuticals Inc. (CGXP) Enzon Pharmaceuticals Inc. (BGEN) Enzon Pharmaceuticals Inc. (GTBP) Enzon Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 293904801 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/08/26 Share - Related Items Shares Outstanding: 0.74 Most Recent Split Date: 3.00 (0.01:1) Beta: -0.04 Market Capitalization: $4.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/08/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - -263.18 ROA 03/31/26 - - 12/31/25 - -10.11 09/30/25 - -6.49 Current Ratio 03/31/26 - - 12/31/25 - 58.57 09/30/25 - 80.86 Quick Ratio 03/31/26 - - 12/31/25 - 58.57 09/30/25 - 80.86 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - -3.40 09/30/25 - -1.24 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©